Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888
Patient who is pregnant and/or breastfeeding
Woman who are pregnant or breastfeeding
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
Breastfeeding should be discontinued if the mother is treated with indenoisoquinolines
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drug
Pregnant or breastfeeding
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Females who are pregnant or breastfeeding are ineligible
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775 (MK-1775)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 and/or romidepsin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2171
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostat
Patients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agents
TUMOR BIOPSY SEQUENCING: Women who are pregnant or breastfeeding
TREATMENT: Women who are pregnant or breastfeeding
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-803
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugs
Women who are pregnant or breastfeeding
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugs
Pregnant and breastfeeding women are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant or breastfeeding women
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-aflibercept
Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN0128
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
If pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-3475
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to treatment with dabrafenib/trametinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449
Breastfeeding should be discontinued if the mother is treated with sEphB4-HSA
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102
Pregnant or nursing; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study therapy* Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775/belinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I7
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 and paclitaxel
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and necitumumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclax
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-570
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 (onalespib)
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) and/or gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavir
Pregnant women and women who are breastfeeding are excluded from this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-110
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT13387
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumab
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL101553
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385